Literature DB >> 32229706

COVID-19 and chronological aging: senolytics and other anti-aging drugs for the treatment or prevention of corona virus infection?

Camillo Sargiacomo1, Federica Sotgia1, Michael P Lisanti1.   

Abstract

COVID-19, also known as SARS-CoV-2, is a new emerging zoonotic corona virus of the SARS (Severe Acute Respiratory Syndrome) and the MERS (Middle East Respiratory Syndrome) family. COVID-19 originated in China and spread world-wide, resulting in the pandemic of 2020. For some reason, COVID-19 shows a considerably higher mortality rate in patients with advanced chronological age. This begs the question as to whether there is a functional association between COVID-19 infection and the process of chronological aging. Two host receptors have been proposed for COVID-19. One is CD26 and the other is ACE-2 (angiotensin-converting enzyme 2). Interestingly, both CD26 and the angiotensin system show associations with senescence. Similarly, two proposed therapeutics for the treatment of COVID-19 infection are Azithromycin and Quercetin, both drugs with significant senolytic activity. Also, Chloroquine-related compounds inhibit the induction of the well-known senescence marker, Beta-galactosidase. Other anti-aging drugs should also be considered, such as Rapamycin and Doxycycline, as they behave as inhibitors of protein synthesis, blocking both SASP and viral replication. Therefore, we wish to speculate that the fight against COVID-19 disease should involve testing the hypothesis that senolytics and other anti-aging drugs may have a prominent role in preventing the transmission of the virus, as well as aid in its treatment. Thus, we propose that new clinical trials may be warranted, as several senolytic and anti-aging therapeutics are existing FDA-approved drugs, with excellent safety profiles, and would be readily available for drug repurposing efforts. As Azithromycin and Doxycycline are both commonly used antibiotics that inhibit viral replication and IL-6 production, we may want to consider this general class of antibiotics that functionally inhibits cellular protein synthesis as a side-effect, for the treatment and prevention of COVID-19 disease.

Entities:  

Keywords:  Azithromycin; COVID-19; Doxycycline; Hydroxy-chloroquine; Quercetin; Rapamycin; aging; antibiotic; corona virus; drug repurposing; prevention; senescence; senolytic drug therapy; viral replication

Year:  2020        PMID: 32229706     DOI: 10.18632/aging.103001

Source DB:  PubMed          Journal:  Aging (Albany NY)        ISSN: 1945-4589            Impact factor:   5.682


  79 in total

Review 1.  Evidence Supporting a Phased Immuno-physiological Approach to COVID-19 From Prevention Through Recovery.

Authors:  S F Yanuck; J Pizzorno; H Messier; K N Fitzgerald
Journal:  Integr Med (Encinitas)       Date:  2020

2.  DeepH-DTA: Deep Learning for Predicting Drug-Target Interactions: A Case Study of COVID-19 Drug Repurposing.

Authors:  Mohamed Abdel-Basset; Hossam Hawash; Mohamed Elhoseny; Ripon K Chakrabortty; Michael Ryan
Journal:  IEEE Access       Date:  2020-09-15       Impact factor: 3.367

3.  Network pharmacology for the identification of phytochemicals in traditional Chinese medicine for COVID-19 that may regulate interleukin-6.

Authors:  Wen-Hao Niu; Feng Wu; Wen-Yue Cao; Zong-Gui Wu; Yu-Chieh Chao; Chun Liang
Journal:  Biosci Rep       Date:  2021-01-29       Impact factor: 3.840

Review 4.  Repurposing of antibiotics for clinical management of COVID-19: a narrative review.

Authors:  Abdourahamane Yacouba; Ahmed Olowo-Okere; Ismaeel Yunusa
Journal:  Ann Clin Microbiol Antimicrob       Date:  2021-05-21       Impact factor: 3.944

Review 5.  Pleiotropic Effects of Tetracyclines in the Management of COVID-19: Emerging Perspectives.

Authors:  Hayder M Al-Kuraishy; Ali I Al-Gareeb; Mohammed Alqarni; Natália Cruz-Martins; Gaber El-Saber Batiha
Journal:  Front Pharmacol       Date:  2021-04-23       Impact factor: 5.810

Review 6.  Advanced glycation end products (AGEs) and its receptor, RAGE, modulate age-dependent COVID-19 morbidity and mortality. A review and hypothesis.

Authors:  Durai Sellegounder; Parisa Zafari; Misagh Rajabinejad; Mahdi Taghadosi; Pankaj Kapahi
Journal:  Int Immunopharmacol       Date:  2021-05-24       Impact factor: 5.714

Review 7.  Therapeutic Effectiveness and Safety of Repurposing Drugs for the Treatment of COVID-19: Position Standing in 2021.

Authors:  Safaet Alam; Taslima Binte Kamal; Md Moklesur Rahman Sarker; Jin-Rong Zhou; S M Abdur Rahman; Isa Naina Mohamed
Journal:  Front Pharmacol       Date:  2021-06-14       Impact factor: 5.810

8.  Porphyromonas gingivalis Provokes Exosome Secretion and Paracrine Immune Senescence in Bystander Dendritic Cells.

Authors:  Ranya Elsayed; Mahmoud Elashiry; Yutao Liu; Ahmed El-Awady; Mark Hamrick; Christopher W Cutler
Journal:  Front Cell Infect Microbiol       Date:  2021-06-01       Impact factor: 5.293

Review 9.  Spices, Condiments, Extra Virgin Olive Oil and Aromas as Not Only Flavorings, but Precious Allies for Our Wellbeing.

Authors:  Irene Dini; Sonia Laneri
Journal:  Antioxidants (Basel)       Date:  2021-05-28

10.  An in vitro study of dual drug combinations of anti-viral agents, antibiotics, and/or hydroxychloroquine against the SARS-CoV-2 virus isolated from hospitalized patients in Surabaya, Indonesia.

Authors:  Andang Miatmoko; Eryk Hendrianto; Deya Karsari; Aristika Dinaryanti; Nora Ertanti; Igo Syaiful Ihsan; Disca Sandyakala Purnama; Tri Pudy Asmarawati; Erika Marfiani; Alfian Nur Rosyid; Prastuti Asta Wulaningrum; Herley Windo Setiawan; Imam Siswanto; Ni Nyoman Tri Puspaningsih
Journal:  PLoS One       Date:  2021-06-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.